Page title (background color coded to the topic category) : PTC:Cancer Risks for Liver Recipients
Introductory message text:
Embedded link to 3 to 5 minute YouTube video (usually a medical professional related to the page topic)
Embedded link to full (30 min to one hour) presentation by medical professional on the page topic introduced above)
Follow-up action plan and next step suggestions
Resources related to this topic for further and deeper information/learning related to this topic:
Skin cancer in liver transplant recipients.
Skin cancer is the most common malignancy arising in the posttransplantation setting. Multiple factors contribute to the high risk for cutaneous carcinoma in immunosuppressed organ-transplant recipients. We review the phenomenon of skin cancer in solid-organ transplant recipients and further delineate the problem in the context of liver transplantation. Skin cancer is a significant medical and surgical problem for organ-transplant recipients. With prolonged allograft function and patient survival, the majority of solid-organ transplant recipients will eventually develop skin cancer. Although squamous cell carcinoma is the most common cutaneous malignancy in this population, basal cell carcinoma, melanoma, and Kaposi's sarcoma, as well as uncommon skin malignancies, may occur. Highly susceptible patients may develop hundreds of squamous cell carcinomas, which may be life threatening. Management strategies focus on regular full-skin and nodal examination, aggressive treatment of established malignancies, and prophylactic measures to reduce the risk for additional photodamage and malignant transformation. Skin cancer is a substantial cause of morbidity and even mortality among solid-organ transplant recipients. As a byproduct of immunosuppression, liver transplant recipients experience a high incidence of skin cancer and should be educated and managed accordingly.
Liver Transplantation and Cancer
- Buell JF, Woodle ES. Syndromic incidence of ovarian cancer after liver transplantation: is breast cancer an antecedent risk? Liver Transpl. 2004;10(1):156–7.
- Husted TL, Neff G, Thomas MJ, Gross TG, Woodle ES, Buell JF. Liver transplantation for primary or metastatic sarcoma to the liver. Am J Transplant. 2006;6(2):392–7.
- Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69(8):1633–7.
- Penn I: Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 110:726–735, 1991.
- Penn I: Post-transplant de novo tumors in liver allograft recipients. Liver Transplant Surg 2:52–59, 1996.
- Penn I: Primary malignancies of the hepato-biliary pancreatic system in organ allograft recipients. J Hepato-Biliary-Pancreatic Surgery 5, 157–164, 1998.
Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: A major cause of late death. Liver Transplant 2001; 7(11 Suppl 1): S109–118.
Jain AB, Yee LD, Nalesnik MA et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193–1200.
Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: Comparison with national cancer incidence rates for England and Wales. Transplantation 2005; 80: 759–764.
Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 2005; 56: 87–99.
Silva MA, Jambulingam PS, Mirza DF. Colorectal cancer after orthotopic liver transplantation. Crit Rev Oncol Hematol 2005; 56: 147–153.
Haagsma EB, Hagens VE, Schaapveld M et al. Increased cancer risk after liver transplantation: A population-based study. J Hepatol 2001; 34: 84–91.
Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, Woodle ES. De novo colorectal cancer: Five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 2005; 37: 960–961.
DISCLAIMER: The content of this TRIO post-transplant cancer Web site is not influenced by sponsors. The site is designed primarily for use by transplant recipients and their supporters. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with your transplant team or a physician skilled in cancer and your organ type if you suspect you are ill.